Brent Saunders, incoming Bausch + Lomb CEO (Richard Drew/AP Images)
February 15, 2023 07:44 AM ESTUpdated 08:24 AM
People
Pharma

Brent Saun­ders to lead Bausch + Lomb in re­turn to CEO slot

Amber Tong

John Carroll

Editor & Founder

Three years af­ter com­plet­ing Al­ler­gan’s $63 bil­lion sale to Ab­b­Vie and walk­ing away with a near­ly $39 mil­lion gold­en para­chute, Brent …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

A service from the Financial Times